ARTICLE | Distillery Therapeutics
Cardiovascular
November 9, 2016 9:00 PM UTC
In vitro studies suggest a KCNQ1 agonist could help treat long QT syndrome (LQTS) caused by KCNQ1 mutations. In Xenopus oocytes expressing eight LQTS-associated KCNQ1 mutations, a previously reported ...
BCIQ Company Profiles
BCIQ Target Profiles